Cargando…
Baricitinib for COVID-19: a suitable treatment? – Authors' reply
Autores principales: | Richardson, Peter J, Corbellino, Mario, Stebbing, Justin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271155/ https://www.ncbi.nlm.nih.gov/pubmed/32251639 http://dx.doi.org/10.1016/S1473-3099(20)30270-X |
Ejemplares similares
-
Baricitinib as the treatment of choice for hospitalised individuals with COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022) -
The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022) -
Baricitinib for COVID-19: a suitable treatment?
por: Favalli, Ennio G, et al.
Publicado: (2020) -
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
por: Stebbing, Justin, et al.
Publicado: (2020) -
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
por: Kalil, Andre C, et al.
Publicado: (2021)